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Abstract: Epithelial to mesenchymal transition (EMT) in cancer is important in therapeutic resistance
and invasiveness. Calcium signaling is key to the induction of EMT in breast cancer cells. Although
inhibition of specific calcium-permeable ion channels regulates the induction of a sub-set of EMT
markers in breast cancer cells, it is still unclear if activation of a specific calcium channel can be a
driver for the induction of EMT events. In this study, we exploited the availability of a selective
pharmacological activator of the calcium-permeable ion channel TRPV4 to assess the direct role of
calcium influx in EMT marker induction. Gene association studies revealed a link between TRPV4
and gene-ontologies associated with EMT and poorer relapse-free survival in lymph node-positive
basal breast cancers. TRPV4 was an important component of the calcium influx phase induced in
MDA-MB-468 breast cancer cells by the EMT inducer epidermal growth factor (EGF). Pharmacological
activation of TRPV4 then drove the induction of a variety of EMT markers in breast cancer cells.
These studies demonstrate that calcium influx through specific pathways appears to be sufficient to
trigger EMT events.
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1. Introduction
Epithelial to mesenchymal transition (EMT) is a fundamental process in embryogenesis and wound
healing and is an important feature of cancer progression [1,2]. EMT in cancer cells represents a change
in cellular phenotype often from a proliferative, epithelial-like state that is typically associated with a
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more rounded cellular morphology and higher levels of E-cadherin (E-Cad) to a more mesenchymal-like
state, that is coupled with a spindle-like morphology, expression of proteins such as vimentin and the
transcription factors Snail and Twist [1,3]. EMT in breast cancer cells is linked to increased cancer cell
invasiveness and therapeutic resistance [1,3,4]. Several cellular signaling pathways are linked to EMT
induction, including Ca2+ signaling [4–6].
Suppression of increases in cytosolic free Ca2+ ([Ca2+]CYT) reduces the induction of EMT genes
normally induced by epidermal growth factor (EGF) and hypoxia in MDA-MB-468 breast cancer
cells [7]. Ca2+ signal-sensitive EMT induction has now been demonstrated in a variety of cancer cell
types, including those of the ovary [8], prostate [9], and liver [10]. However, it is clearly the nature
of the calcium signal that is important in EMT induction since not all stimuli that elevate [Ca2+]CYT
induce EMT [7], and in many cases silencing of calcium-permeable ion channels such as TRPM7,
TRPC1, and ORAI1 only inhibit the induction of some EMT markers [7,11,12]. Although there are
widely available pharmacological activators for calcium-permeable ion channels such as the L-type
voltage-gated Ca2+ channel activator BAYK8644 [13] and the TRPV1 activator capsaicin [14], the lack of
readily available pharmacological activators for specific ion channels associated with EMT induction
in cancer cells has made it difficult to fully define the role of the calcium signal in EMT. If Ca2+ influx
via a specific pathway is sufficient to induce EMT, it would demonstrate that Ca2+ influx is not simply
a required co-factor for established EMT inducing cellular signaling pathways but sufficient to elicit a
response on its own. One calcium-permeable ion channel with indirect links to EMT and with a potent
pharmacological activator is TRPV4 [15,16].
TRPV4 is a cation permeable ion channel with roles in osmotic and temperature sensing that is
activated by a variety of endogenous factors (including arachidonic acid metabolites) and is a therapeutic
target for several conditions, including pulmonary edema [17]. In breast cancer, TRPV4 levels are
elevated in basal-like breast cancers compared with other molecular breast cancer subtypes [18,19].
Silencing of TRPV4 reduces migration and invasiveness in mouse 4T07 mammary cancer cells in vitro
and suppresses the metastasis of 4T1 breast cancer cells in vivo [18]. The links between TRPV4 and EMT
in breast cancer have so far been indirect and include the positive correlation between an “EMT score”
and TRPV4 gene expression in human breast cancer samples [18], and the ability of the non-specific
TRPV4 activator 4α-PDD to reduce E-cadherin levels in mouse 4T07 mammary cancer cells [20].
TRPV4 is associated with some aspects of EMT induced by specific stimuli such as transforming
growth factor β1 (TGFβ1) in keratinocytes [15]; however, the ability of TRPV4 activation or indeed any
calcium-permeable ion channel to induce EMT is unknown. In these studies, we sought to explore the
relationship between TRPV4 gene expression levels and breast cancer molecular subtypes, prognosis,
and EMT. Furthermore, we exploited selective TRPV4 pharmacological inhibition and activation to
define the role of TRPV4 in EMT induction and to determine if activation of a specific calcium-permeable
ion channel is sufficient to induce EMT in breast cancer cells.
2. Results
2.1. TRPV4 Expression Associates with Tumor Dissemination
TRPV4 expression is elevated in basal-like breast tumors compared to other molecular subtypes [18,19].
We have previously demonstrated that TRPV4 expression is also associated with a breast cancer gene
cluster (referred to as Red Module) that is strongly associated with EGFR, a gene often involved in
the EMT process [19]. Basal-like breast tumors are highly heterogeneous, so to further explore the
role of TRPV4 in this cancer type, we interrogated the Red Module by analyzing the gene-ontology
of the top 100 most interconnected genes (Table S1) within this cluster (Figure 1A). This analysis
revealed processes and cellular components involved in broad and general developmental processes.
Gene expression of the Red Module across breast tumors revealed elevated expression in basal-like
tumors, as previously identified [19]; however, there were some genes within this cluster that appeared
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to have heterogeneous expression within basal-like tumors (Figure 1B). Additionally, the Red Module
was highly elevated in a subset of normal-like and luminal A tumors.
Figure 1. TRPV4 expression associates with tumor dissemination. (A) Gene ontology analysis of the Top
30 interconnected genes from the gene network module (Red Module) that TRPV4 is associated with
and reveals links to biological processes and cellular components typical of developmental processes.
(B) Hierarchical clustering of normalized gene expression from the Cancer Genome Atlas (TCGA)
data focused on known markers of disease progression in breast cancer, including those that regulate
epithelial to mesenchymal transition (EMT), TRPV channels, and the weighted gene co-expression
network analysis (WGCNA) module. Expression values are mean-centered log2 normalized RNA-seq
by expectation maximization (RSEM) values from breast cancer patients in the TCGA cohort. Basal-like
tumors are noted. (C,D) Stratification of relapse-free survival (RFS) by TRPV4 and Red Module gene
expression, respectively, in patients with basal-like breast cancer, separated by lymph node status.
Patient numbers, p-value, and hazard ratios are indicated within the figure.
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To further explore this heterogeneity in basal-like tumors, we stratified the relapse-free survival of
patients with basal breast cancers and grouped them based on their lymph node (LN) status. This analysis
revealed that high TRPV4 expression is a significant marker for patients with LN+ basal breast
tumors, but not for patients with LN- disease (Figure 1C). Exploring the Red Module with these same
parameters demonstrates that this module stratifies both LN- and LN+ disease, but intriguingly in LN-
patients, high levels of this gene cluster are a predictor of better outcomes (Figure 1D); in contrast,
high levels predict poor outcome in LN+ patients, similar to high TRPV4 expression (Figure 1D).
2.2. Regulation of Ca2+ Influx and Vimentin Protein Expression by TRPV4
The analysis described above indicated an association between TRPV4 and gene-ontologies associated
with EMT, such as those linked to development. Given the indirect association between TRPV4 expression
and EMT in breast cancer [15,18,20] and the importance of Ca2+ signaling in EMT [7], we sought to
assess the possible role of TRPV4 in EMT induction. Our detailed assessment began with defining
the contribution of TRPV4 to the sustained phase of Ca2+ influx induced by a variety of activators in
EMT-inducible MDA-MB-468 breast cancer cells. Purinergic receptor activation produced a sustained
increase in [Ca2+]CYT (Figure 2A), which previous studies have shown to be sensitive to inhibitors
of store-operated Ca2+ entry mediated by Orai1 Ca2+ channels [21]. Neither the initial increase in
[Ca2+]CYT elicited by ATP (Figure 2B) nor the sustained Ca2+ influx phase (Figure 2C) was sensitive to
TRPV4 inhibitor HC067047. Assessment of [Ca2+]CYT induced by low concentration of trypsin activating
protease-activated receptor 2 (PAR2) (Figure 2D) showed that the sustained Ca2+ influx following PAR2
activation in MDA-MB-468 was in part mediated by TRPV4 (Figure 2E,F). Likewise, sustained Ca2+ influx
induced by EGF (Figure 2G) was attenuated by TRPV4 inhibition (Figure 2H,I).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 16 
 
 
Figure 2. Regulation of Ca2+ influx and vimentin protein expression by TRPV4 in MDA-MB-468 cells. 
Average [Ca2+]CYT transients with 100 µM ATP (A), 10 nM trypsin (D) and 50 ng/mL EGF addition (G) 
with or without HC067047 treatment (10 µM, 15 min pre-incubation and maintained throughout 
experiment). (B,E,H) Quantification of relative maximum peak corresponding to Ca2+ release from the 
ER and (C,F,I) quantification of relative [Ca2+]CYT at 800 s corresponding to Ca2+ influx. Pooled data 
from three independent experiments, mean ± SD, ns = not significant, * p < 0.05, *** p < 0.001. (unpaired 
t-test). Representative western blot (left) and densitometric analysis of three independent experiments 
(right) of the effect of pharmacological inhibition of TRPV4 using HC067047 (HC) or TRPV4 siRNA-
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Figure 2. Regulation of Ca2+ influx and vimentin protein expression by TRPV4 in MDA-MB-468
cells. Average [Ca2+]CYT transients with 100 µM ATP (A), 10 nM trypsin (D) and 50 ng/mL EGF
addition (G) with or without HC067047 treatment (10 µM, 15 min pre-incubation and maintained
throughout experiment). (B,E,H) Quantification of relative maximum peak corresponding to Ca2+
release from the ER and (C,F,I) quantification of relative [Ca2+]CYT at 800 s corresponding to
Ca2+ influx. Pooled data from three independent experiments, mean ± SD, ns = not significant,
* p < 0.05, *** p < 0.001. (unpaired t-test). Representative western blot (left) and densitometric
analysis of three independent experiments (right) of the effect of pharmacological inhibition of
TRPV4 using HC067047 (HC) or TRPV4 siRNA-mediated silencing on (J,K) EGF-mediated (50 ng/mL
for 24 h) and (L,M) hypoxia-mediated (1% O2 for 48 h) induction of vimentin protein expression.
ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA, with Dunnett’s
multiple comparisons, treatment groups compared to the second bar (EGF/hypoxia-induced control
groups), n = 3, mean ± SD. NT= non-targeting.
The ability of TRPV4 pharmacological inhibition to reduce Ca2+ influx produced by EGF
(Figure 2G–I) led us to assess the consequences of TRPV4 pharmacological inhibition and silencing
on EGF-mediated induction of the EMT marker vimentin, which is sensitive to TRPM7 inhibition
in the same model [7]. HC067047 produced a significant and concentration-dependent inhibition of
EGF-induced vimentin protein expression (Figure 2J). TRPV4 silencing (Figure S1) also significantly
reduced the induction of vimentin expression by EGF (Figure 2K). TRPV4 pharmacological inhibition
and silencing both reduced vimentin induction produced by hypoxia in this model (Figure 2L,M),
another EMT inducer [7,22,23].
2.3. Promotion of EMT by TRPV4 Activation
To determine whether TRPV4 mediated Ca2+ influx can drive EMT marker induction in this model,
breast cancer cells were treated with low concentrations of the selective TRPV4 pharmacological activator
GSK1016790A [16]. The concentrations of GSK1016790A were selected to be less than the EC50 for
[Ca2+]CYT increases in this breast cancer cell line (EC50 ~ 15 nM) and below the concentrations associated
with cell death due to excessive sustained Ca2+ influx [19]. TRPV4 activation with GSK1016790A (1 nM)
was sufficient to significantly increase mRNA levels of the EMT markers vimentin, N-cadherin, AXL,
and SERPINE1 (Figure 3A–D). In all cases, this was abolished with TRPV4 silencing (Figure 3A–D).
There was no significant induction of the EMT transcription factors Twist and Snail1 (Figure 3E,F);
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however, there was a significant increase in the stemness marker CD44/CD24 ratio with TRPV4
activation, and this was also eliminated with TRPV4 silencing (Figure 3G). TRPV4 pharmacological
activation also induced EMT protein marker changes, as evident by the upregulation of vimentin
protein (a mesenchymal marker) and downregulation of E-cadherin (an epithelial marker), which were
also abolished by TRPV4 silencing (Figure 3H–J).Int. J. Mo . Sci. 2020, 21, x FOR PEER REVIEW 7 of 16 
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Figure 3. TRPV4 activation promotes EMT in MDA-MB-468 cells. (A–G) The effect of TRPV4
pharmacological activator, GSK1016790A (GSK101), on the mRNA expression of EMT markers
in MDA-MB-468 cells treated with non-targeting siRNA (siNT) or TRPV4 siRNA (siTRPV4).
ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (two-way ANOVA, with Tukey’s
multiple comparisons), n = 3, mean ± SD. Representative western blot (H) and densitometric analysis
of three independent experiments (I,J) of the effect of GSK101 in TRPV4-silenced and control cells
on the protein expression of vimentin and E-cadherin. ns=not significant, * p < 0.05, **** p < 0.0001
(one-way ANOVA, with Tukey’s multiple comparisons), n = 3, mean ± SD.
Assessment of the consequences of GSK1016790A treatment in another model of EMT in breast cancer
cells supported the ability of TRPV4 activation to induce EMT marker expression. GSK1016790A produced
a general trend in EMT marker mRNA levels in PMC42LA breast cancer cells with significant increases in
Snail, vimentin, AXL, SERPINE1, and CD44 (Figure 4A–G). However, in all cases, the degree of increase
was less than that induced by EGF and was less than the changes observed in MDA-MB-468 breast cancer
cells. This may be reflective of less TRPV4 expression in PMC42LA breast cancer cells (Figure S2). Similar
effects were seen with the induction of protein levels of the EMT marker vimentin (Figure 4H,I).
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Figure 4. TRPV4 activation promotes EMT in PMC42LA cells. (A–G) The effect of TRPV4
pharmacological activator, GSK1016790A (GSK101), and EGF (10 ng/mL) on the mRNA expression of
EMT markers in PMC42LA cells. Representative western blot (H) and densitometric analysis of three
independent experiments (I) of the effect of GSK101 and EGF in TRPV4-silenced and control cells on
vimentin protein expression in PMC42LA cells. ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001, unpaired t-test, GSK101 compared to the dimethyl sulfoxide (DMSO) control, and EGF
compared to its acetic acid (AA) control, n = 3, mean ± SD.
2.4. Regulation of Cell Motility by TRPV4
One of the consequences of EMT can be a more migratory phenotype. To explore if TRPV4 may
play a role in the migration MDA-MB-468 b ast cancer cells, the effects of TRPV4 silencing
on single-cell migration was assessed. TRPV4 silencing (Figure 5A,B) significantly attenuated the
accumulated distance traveled of single MDA-MB-468 breast cancer cells (Figure 5C).
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Figure 5. TRPV4 silencing reduces single-cell motility in MDA-MB-468 cells. Immunoblotting studies
(A) and densitometry analysis (B) showing TRPV4 siRNA silencing, reducing TRPV4 protein levels by
around 90%. **** p < 0.0001 compar d with control (unpa red t-test), n = 3, mean ± SD. (C) A collagen-
based model and individual cell tracking system were used to assess and qua tify the migration of
MDA-MB-468 breast cancer cells treated with non-targeting (NT) siRNA (total of 84 cells) and TRPV4
siRNA (total of 72 cells). In this model, the accumulative distance of individu l c lls migrated over
the course of 12 h post-exposure to hypoxia (24 h) is assessed. **** p < 0.0001, (unpaired t-test).
Gr ph represents the mean ± SD for three i dependent exp riments.
3. Discussion
Basal-like breast tumors have elevated levels of TRPV4; however, the expression of TRPV4 within
this breast cancer subtype is heterogeneous [18,19]. Our further assessment of basal-like breast cancers
suggests that TRPV4 may contribute to or correlate with more invasive disease, given its association
with poorer relapse-free survival in LN+ basal breast cancers but not LN-. Moreover, a gene cluster,
which is associated with developmental processes and elevated expression in basal-like tumors [19],
also stratifies patients with LN+ disease. These data suggest that TRPV4 might be part of a broader
network of genes that are involved in the fundamental developmental process, such as EMT, that is
utilized by tumors to progress invasion to the lymph nodes and beyond.
Increases in [Ca2+]CYT can be achieved in breast cancer cells through the release of calcium from
internal stores or the influx of Ca2+ ions across the plasma membrane. In some cases, the influx of Ca2+
is triggered by the release of Ca2+ from intracellular Ca2+ stores and influx through Orai1 channels.
However, other channels can also contribute to Ca2+ influx after cell activation. For example, TRPV4
mediated Ca2+ influx occurs in a variety of cell types after stimulation of plasmalemmal receptors.
Indeed, sustained Ca2+ influx induced by PAR2 activation is partly mediated via TRPV4, and this may
be important in inflammatory pathways [24]. Our assessment of Ca2+ influx induced by a variety
of stimuli demonstrated the differential contribution of TRPV4 to sustained Ca2+ influx induced by
the purinergic receptor activator ATP, the PAR2 activator trypsin, and EGF in MDA-MB-468 breast
cancer cells. ATP elicited a sustained increase in Ca2+ influx that was insensitive to TRPV4 inhibition.
Although this could reflect an ability of ATP to induce Ca2+ influx by P2X channels, this is not the
case given this sustained phase of Ca2+ influx is mediated by store-operated calcium influx in this
model [21]. In contrast, the trypsin-induced Ca2+ influx was attenuated by TRPV4 pharmacological
inhibition. Likewise, the sustained phase of Ca2+ increase induced by EGF was reduced by TRPV4
pharmacological inhibition, like the TRPV4-sensitive EGF activation pathways reported in renal and
corneal epithelial cells [25,26]. In all cases, TRPV4 pharmacological inhibition had no effect on Ca2+
release from internal stores as reflected in similar initial peak [Ca2+]CYT induced by all agents in the
presence of HC067047.
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A variety of EMT inducers are sensitive to intracellular Ca2+ chelation, and specific Ca2+ permeable
ion channels can regulate EMT. However, in many cases, these Ca2+ permeable ion channels regulate
only specific EMT markers and/or are specific to particular EMT inducers [7,11]. In contrast, our studies
show that TRPV4 silencing and pharmacological inhibition attenuates vimentin protein induction
induced by both EGF and hypoxia. The effect of the TRPV4 pharmacological inhibitor was greater
than TRPV4 silencing on EGF-mediated effects. The TRPV4 pharmacological inhibitor at a maximal
concentration will almost completely block TRPV4 channel activity, whereas siRNA mediated silencing
will likely still leave around 10% of TRPV4 channels that could still be fully activated. The potential of
TRPV4 to be of fundamental and direct importance in EMT induction was demonstrated through our
assessment of direct TRPV4 activation with GSK1016790A. Direct TRPV4 activation increased levels of
an array of mesenchymal markers and suppressed levels of the epithelial marker E-cadherin, all of
which were abolished by TRPV4 silencing. These studies also indicate that at least some ion channels
are not simply augmenters of EMT-inducing signals but appear to induce EMT in their own right.
This may be important, given that some ion channels are activated by a variety of endogenous stimuli,
such as is the case for TRPV4, where activation can be produced by mechanical deformation, changes
in osmotic pressure, temperature, pH, and metabolites of arachidonic acid [27]. However, our studies
do indicate that the ability and degree of ion channel-mediated EMT induction will be critically
dependent on expression levels and appropriate cellular localization. MDA-MB-468 breast cancer cells
where TRPV4 activation produced robust induction of EMT have high levels of TRPV4, in contrast to
PMC42LA cells where TRPV4 levels are substantially lower and where TRPV4 activation produced far
more modest and less diverse induction of EMT markers. The characterization of endogenous TRPV4
currents in MDA-MB-468 breast cancer cell lines is now warranted, given the potential role of such
calcium influx in regulating cellular plasticity in this cell line
These studies highlight a new complexity and dimension to the targeting of some ion channels
in breast cancer. Pronounced overexpression of TRPV4 in some breast cancers has been exploited
in vitro and in vivo through pharmacological activation and subsequent promotion of cell death and
suppression of tumor growth [19]. In a lung cancer model, TRPV4 activation normalizes tumor
vasculature and promotes the effectiveness of chemotherapy [28]. However, these studies show that
even very modest pharmacological activation of TRPV4 can promote EMT and breast cancer cell
migration in the same model. Hence, dosing regimens may be critical for calcium-induced cell death in
cancers that overexpress TRPV4, with maintained high levels of activator and/or combination with other
agents required. Our results also provide evidence that TRPV4 inhibition may have anti-metastatic
effects through effects on cancer cell migration [18] and also through reducing metastatic initiation
via effects on EMT. The known role of EMT in the development of therapeutic resistance [5] provides
another dimension to TRPV4 inhibition for the treatment of some breast cancers, the feasibility of which
is demonstrated by the clinical trials of TRPV4 inhibitors for heart failure [29]. Given the temperature
sensitivity of TRPV4 [30], future studies should assess the temperature effects of some of our identified
phenotypes and effects, which may require the use of genetically encoded Ca2+ indicators, which are
less prone to sequestration into intracellular organelles.
4. Materials and Methods
4.1. Cell Culture
The MDA-MB-468 human breast cancer cell line was obtained from The Brisbane Breast Bank,
UQCCR, Brisbane, Australia, and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
with high glucose (D6546; Sigma-Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine
serum (FBS) and 4 mM L-glutamine (25030; Thermo Fisher Scientific, Waltham, MA, USA). PMC42LA
human breast cancer cell line was obtained from Dr Leigh Auckland, Deakin University, Melbourne,
Australia [31,32], and maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (11875085;
Life Technologies, Carlsbad, CA, USA) with 10% FBS. Cells were maintained at 37 ◦C and 5% CO2 in a
Int. J. Mol. Sci. 2020, 21, 9417 10 of 14
humidified incubator. For hypoxia experiments, cells were placed in a hypoxic incubator (37 ◦C, 1% O2,
5% CO2, and 94% N2) for durations stated in the results. Cells were examined for mycoplasma every
six months using MycoAlert kit (Lonza, Basel, Switzerland) and validated by short tandem repeat
(STR) profiling using The GenePrint® 10 System (Promega, Madison, WA, USA) at the Queensland
Institute of Medical Research (QIMR) Berghofer Medical Research Institute, Brisbane, Australia.
4.2. Quantitative Real-Time RT–PCR
RNA isolation, purification, and synthesis of cDNA were performed as previously described [12].
Quantitative PCR was performed using TaqMan Gene Expression Assays and Fast Universal PCR Master
Mix (4352042; Life Technologies, Carlsbad, CA, USA) in a StepOnePlusTM Real-Time PCR instrument
(Life Technologies). The following specific TaqMan Gene Expression Assays were used: vimentin
(Hs00185584_m1), N-cadherin (Hs00983062_m1), AXL (Hs01064444_m1), SERPINE1 (Hs01126606_m1),
Twist (Hs00361186_m1), Snail1 (Hs00195591_m1), CD44 (Hs01075861_m1), and CD24 (Hs02379687_s1).
Comparative CT (∆∆CT) method and normalization to the ribosomal 18S sRNA (Gene Expression
Assay 4319413E) were used to calculate relative target mRNA levels.
4.3. Immunoblotting
Protein isolation, immunoblotting, and densitometric analysis were performed as previously
described [9]. Primary antibodies included vimentin (V6389, 1:750 dilution, Sigma-Aldrich), E-cadherin
(14472, 1:1000 dilution, Cell Signaling Technology, Danvers, MA, USA), TRPV4 (ab39260, 1:500 dilution,
Abcam, Melbourne, VIC, Australia), and β-actin (A5441, 1:10,000 dilution, Sigma-Aldrich). Secondary
antibodies included goat anti-rabbit (170-6515, 1:10,000 dilution, Bio-Rad, Hercules, CA, USA) and goat
anti-mouse (170-6516, 1:10,000 dilution, Bio-Rad) horseradish peroxidase conjugate. Vimentin, E-cadherin,
and TRPV4 antibodies were incubated with membranes overnight at 4 ◦C in 5% non-fat milk. β-Actin
and secondary antibodies were incubated for 1 h at room temperature.
4.4. siRNA Silencing
Dharmacon ON-TARGETplus SMARTpool siRNAs (a mixture of four rationally designed siRNAs;
Millennium Science, Mulgrave, VIC, Australia) and DharmaFECT4 Transfection Reagent (0.1 µL per well)
were used to transfect non-targeting siRNA (siNT; D-001810-10) or TRPV4 siRNAs (siTRPV4; L-004195-00)
into the MDA-MB-468 cells. Cells were seeded at a density of 1 × 104 (for EGF or GSK1016790A
experiments) or 6 × 103 (for 48 h hypoxia exposure) in 96-well plates and were transfected with siRNAs
24 h post-seeding.
4.5. Cell Migration Assay
Collagen matrices and live-cell imaging were used to assess cell motility. Ninety-six-well plates were
coated with 50 µM collagen mixture comprising of 10× phosphate-buffered saline (8% volume/volume),
DMEM (24% volume/volume), and collagen type I from bovine skin (C4243, Sigma-Aldrich) at a final
concentration of 2 mg/mL), adjusted to physiological pH with 1 M NaOH. Plates were incubated at 37 ◦C,
5% CO2 for 1 h to form collagen gels. MDA-MB-468 cells were then seeded on top of the collagen gel at
a density of 1000 cells per well. siRNA-mediated silencing of TRPV4 was conducted 24 h post-seeding
as described above. Post silencing (24 h), cells were serum reduced (0.5% FBS) for 48 h and positioned
on the stage of a JuLiTM Stage Live Cell Imaging System (NanoEnTek Inc., Seoul, Korea) in a 37 ◦C
hypoxia incubator. Starting from 72 h post exposure to hypoxia, bright field images (4×magnification)
were captured from the center of wells every 15 min for a period of 12 h. The Manual Tracking plug-in of
the ImageJ 1.49q software (NIH, Bethesda, MD, USA, https://imagej.nih.gov/ij/) was used to track single
cells. Calculation and illustration of single cell movement over the 12 h period, were conducted using the
Chemotaxis and Migration Tool V2.0 (Ibidi, Munich, Germany).
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4.6. Measurement of Cytosolic Free Ca2+
[Ca2+]CYT was measured in 96-well black CellBIND plates (CLS3340; Corning, Corning, NY, USA)
using a fluorometric Imaging Plate Reader (FLIPRTETRA, Molecular Devices, San Jose, CA, USA) and a
PBX no-wash Ca2+ Assay Kit (640175, BD Biosciences, San Jose, CA, USA) as previously described [33].
Calcium measurements were performed at room temperature. Data analysis was conducted using the
ScreenWorks Software (v2.0.0.27, Molecular Devices). The response over baseline was measured as a
relative measure of [Ca2+]CYT. Relative maximum peak and relative [Ca2+]CYT at 800 s were calculated.
4.7. Patient Survival Analysis
Stratification of patient survival by TRPV4 and Red Module expression was done using the online
survival analysis tool Kaplan-Meier Plotter [34]. Patients were stratified based on the TRPV4 probe
219516_at or the mean expression of the top 30 genes from the Red Module (Table S1), “Auto select best
cutoff”, relapse-free survival (RFS), and lymph node status in women with Basal breast tumors (ER-
and HER2-negative samples). Gene expression levels were determined by Kaplan-Meier Plotter and
displayed as “low” (black line) or “high” (red line). The significance of stratification was determined
by log-rank p-value and hazard ratios (HR) with 95% confidence intervals.
4.8. Gene Correlation Analysis
RNA-Seq data for breast cancer molecular markers, TRPV channels, and genes with the weighted
gene co-expression network analysis (WGCNA) correlated network were sourced from the Cancer Genome
Atlas (TCGA) [35] network via cBioPotal for Cancer Genomics [36,37]. In total, data for 1044 patients
were analyzed, which includes 117 Basal-like (Basal), 59 HER2-Enriched (HER2), 361 Luminal A (LumA),
169 Luminal B (LumB), 113 Normal-like (N-Like), and 225 not yet classified tumors. RNA-Seq data
were downloaded at RNA-seq by expectation maximization (RSEM [38]) and transformed via log2
mean-centering of expression for each gene. Normalized expression values were then clustered via
Manhattan-based average-linkage clustering in Multiple Experiment Viewer (MeV [39]).
4.9. Weighted Correlation Network Analysis
Gene expression data for breast tumors were accessed from The Cancer Genome Atlas (TCGA)
Project [35]; a total of 845 samples were analyzed, which included samples from all major breast tumor
molecular subgroupings. Expression was analyzed using Weighted Co-expression Gene Network Analysis
(WGCNA) in the R environment, as previously published [19]. In brief, WGCNA of breast tumor gene
mRNA expression identified a co-regulated gene cluster, which included TRPV family genes, and this
cluster was referenced by a color identifier as “Red Module”. Using measures of interconnectedness
within and between modules, the 100 topmost interconnected genes of the Red Module were identified
(Table S1). Gene ontology analysis was performed using the AmiGO [40] bioinformatics tool (http:
//amigo.geneontology.org/amigo), with Bonferroni multiple-comparison correction.
4.10. Weighted Correlation Network Analysis
GraphPad Prism (La Jolla, CA, USA, www.graphpad.com) was used for statistical analysis.
Specific statistical tests and significance for each experiment are stated in corresponding figure legends.
5. Conclusions
In summary, TRPV4 is a receptor-selective regulator of activated calcium influx in breast cancer
cells that overexpress TRPV4 and pharmacological activation of TRPV4 is sufficient to induce EMT
in these cells. Our studies highlight new roles for TRPV4 in breast cancer and identify that some ion
channels are not just regulators of specific elements of EMT but can be the driver of this phenomenon.
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